Solvias, a pharmaceutical service provider, has appointed Karen Huebscher to succeed Hansjörg Walther as CEO. Walther will retire and hand over operational management of the company to Huebscher, effective March 1, 2014. In 2000, Huebscher became head of investor relations at Novartis. In 2006, she joined the global executive leadership team of the Vaccines and Diagnostics division, headquartered in the United States.
As a member of the Executive Committee, Huebscher was responsible for business development (in-and out licensing) and M&A. After her return from the US, Huebscher took on responsibility for vaccine marketing in Europe and became site head for the Vaccines & Diagnostics division in Basel. In 2012, she founded Fibula Medical and was also appointed to the Board of Directors of Tecan. Huebscher has been a member of the Board of Directors of Solvias since 2013. Walther will retain his seat on the Board of Directors.